(Q44716331)

5 December 2017

title

Pharmacokinetics of nafamostat mesilate during continuous hemodiafiltration with a polyacrylonitrile membrane (English)

1 reference

5 December 2017

1 reference

Hajime Nakae

1

1 reference

5 December 2017

Kimitaka Tajimi

series ordinal

2

1 reference

5 December 2017

publication date

1 October 2003

1 reference

Therapeutic Apheresis and Dialysis

5 December 2017

published in

1 reference

5 December 2017

volume

7

1 reference

5 December 2017

issue

5

1 reference

5 December 2017

page(s)

483-485

1 reference

Multiple organ dysfunction score: a reliable descriptor of a complex clinical outcome

5 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1526-0968.2003.00088.X

New synthetic inhibitors of C1r̄, C1 esterase, thrombin, plasmin, kallikrein and trypsin

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1526-0968.2003.00088.X

Agonists of proteinase-activated receptor 2 induce inflammation by a neurogenic mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1526-0968.2003.00088.X

Effect of nafamostat mesilate on Na+ and K+ transport properties in the rabbit cortical collecting duct

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1526-0968.2003.00088.X

Effectiveness of combining plasma exchange and continuous hemodiafiltration (combined modality therapy in a parallel circuit) in the treatment of patients with acute hepatic failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1526-0968.2003.00088.X

Cytokine removal by plasma exchange with continuous hemodiafiltration in critically ill patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1526-0968.2003.00088.X

Nafamostat Mesylate as Anticoagulant in Continuous Hemofiltration and Continuous Hemodiafiltration

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1526-0968.2003.00088.X

Pharmacological studies of FUT-175, nafamstat mesilate. I. Inhibition of protease activity in in vitro and in vivo experiments.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1526-0968.2003.00088.X

Effect of nafamostat mesilate on pulmonary vascular injury induced by lipopolysaccharide in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1526-0968.2003.00088.X

Involvement of NF-kappa B activation in thrombin-induced human vascular smooth muscle cell proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1526-0968.2003.00088.X

Hyperkalemia due to nafamostat mesylate

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1526-0968.2003.00088.X

10.1046/J.1526-0968.2003.00088.X

21 January 2018

Identifiers

DOI

1 reference

5 December 2017

1 reference